Development and Evaluation of [ 68 Ga]Ga-FA-PSMA: A Folic Acid-Conjugated PSMA-Targeting Radiotracer for Enhanced PET Imaging of Prostate Cancer
Bioconjugate Chemistry · 2026
DOI: 10.1021/acs.bioconjchem.5c00597 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioconjugate Chemistry, 2026. Verfasst von Yukai Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Folic Acid, Gallium Radioisotopes, Glutamate Carboxypeptidase II. Die Arbeit nennt 32 Literaturangaben. Gefördert von: Shanghai Jiao Tong University, National Key Research and Development Program of China, Shanghai Key Laboratory of Molecular Imaging.
Abstract (Originalsprache)
Prostate-specific membrane antigen (PSMA) is a critical biomarker for prostate cancer. While current radiotracers like [68Ga]Ga-PSMA-11 are clinically useful, enhancing tumor uptake and contrast remains a goal. Capitalizing on PSMA's enzymatic hydrolysis of folate polyglutamates, we report the design, synthesis, and biological evaluation of a novel heterobivalent PSMA-targeted radiotracer, [68Ga]Ga-FA-PSMA. In vitro experiments revealed a significantly enhanced binding affinity of FA-PSMA for human PSMA (KD = 3.268 nM) compared to PSMA-11 (KD = 47.88 nM) and free FA (KD = 424.3 nM). In vivo micro-PET/CT imaging and biodistribution studies in PSMA-positive (22RV1) xenograft models demonstrated superior performance over [68Ga]Ga-PSMA-11. [68Ga]Ga-FA-PSMA exhibited significantly higher peak tumor SUVmax (1.06 ± 0.09 vs 0.80 ± 0.08 at 210 min p.i.) and tumor accumulation (2.74 ± 0.40 vs 1.75 ± 0.74 %ID/g at 2 h p.i.), alongside significantly enhanced tumor-to-background ratios, particularly tumor-to-blood (10.41 ± 3.41 vs 2.11 ± 0.89) and tumor-to-muscle (10.07 ± 0.73 vs 6.03 ± 1.33) at 2 h p.i. Furthermore, [68Ga]Ga-FA-PSMA demonstrated reduced renal uptake (30.80 ± 8.54 vs 38.71 ± 9.72 %ID/g at 2 h p.i.), high in vitro stability, and favorable hydrophilicity (LogP = -3.76). These findings demonstrate that the novel heterobivalent tracer [68Ga]Ga-FA-PSMA offers significantly enhanced PSMA-targeting affinity, tumor uptake, and imaging contrast compared to the clinical standard, validating the FA-conjugation strategy and positioning it as a highly promising next-generation diagnostic agent for precise prostate cancer imaging.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China.
- MOE Key Lab of Resource Chemistry, Joint International Research Laboratory of Resource Chemistry of Ministry of Education, Shanghai Key Laboratory of Rare Earth Functional Materials, and Shanghai Frontiers Science Centr…
ORCID-Profile: Jingye Li, Bowu Zhang, Jianjun Liu, Cheng Wang
Förderung
- Shanghai Jiao Tong University
- National Key Research and Development Program of China
- Shanghai Key Laboratory of Molecular Imaging
Zitieren
APA
Zhang, Y., Zhang, Q., Li, J., Zhang, B., Liu, J., & Wang, C. (2026). Development and Evaluation of [ 68 Ga]Ga-FA-PSMA: A Folic Acid-Conjugated PSMA-Targeting Radiotracer for Enhanced PET Imaging of Prostate Cancer. Bioconjugate Chemistry. https://doi.org/10.1021/acs.bioconjchem.5c00597
Vancouver
Zhang Y, Zhang Q, Li J, Zhang B, Liu J, Wang C. Development and Evaluation of [ 68 Ga]Ga-FA-PSMA: A Folic Acid-Conjugated PSMA-Targeting Radiotracer for Enhanced PET Imaging of Prostate Cancer. Bioconjugate Chemistry. 2026. doi:10.1021/acs.bioconjchem.5c00597
BibTeX
@article{Zhang2026,
author = {Zhang, Yukai and Zhang, Qingyu and Li, Jingye and Zhang, Bowu and Liu, Jianjun and Wang, Cheng},
title = {Development and Evaluation of [ 68 Ga]Ga-FA-PSMA: A Folic Acid-Conjugated PSMA-Targeting Radiotracer for Enhanced PET Imaging of Prostate Cancer},
journal = {Bioconjugate Chemistry},
year = {2026},
doi = {10.1021/acs.bioconjchem.5c00597}
}
EUVIMED